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involved patients with complex disease and
other mitigating factors. We therefore con-
tinue not only to use the connector but to
promote its use to our colleagues.
R. L. Quigley, MD, PhD
Division of Cardiothoracic Surgery
Albert Einstein Medical Center
Philadelphia, PA 19141
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Reply to the Editor:
Since submission of our report, we too
have begun to administer clopidogrel rou-
tinely, 75 mg by mouth every morning
starting on the first postoperative morning
and continuing through the second postop-
erative month. We have detected no new
problems.
Baron Hamman, MD
Division of Cardiovascular Surgery
Baylor University Medical Center
Dallas, TX 75246
doi:10.1067/mtc.2003.283
Symmetry aortic connector system
To the Editor:
The article by Donsky and colleagues1 re-
garding thrombotic occlusion of vein grafts
after use of the Symmetry aortic connector
system (St Jude Medical, Inc, St Paul,
Minn) aroused my interest because of my
experience with this device. Similar to the
authors’ experience, I have had occlusion
of the aortic orifice at the connector site
within a few months of surgery in 3 pa-
tients. All patients were obese, diabetic,
and hypertensive, as in the patients refer-
enced in the article. It has been my expe-
rience, however, that these occlusions oc-
cur when a small (gray) connector is used,
but not when a large (blue or purple) con-
nector can be used. The authors do not
mention the size of the connectors used in
their case report. I would like to ask their
opinion regarding my observation.
Terrill E. Theman, MD
701 Ostrum St, Suite 201
Bethlehem, PA 18015
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Reply to the Editor:
Size of the connector was not recorded in
the permanent record.
Baron Hamman, MD
Division of Cardiovascular Surgery
Baylor University Medical Center
Dallas, TX 75246
doi:10.1067/mtc.2003.285
Does normothermic cardiopulmonary
bypass influence clinical outcomes,
cytokine production, and in vitro
platelet function?
To the Editor:
We read with great interest the article by
Gaudino and associates1 in the June 2002
issue of this Journal. They evaluated pro-
spectively the clinical outcomes of pa-
tients and some inflammatory and fi-
brinolytic markers such as C-reactive
protein, interleukin (IL) 6, prothrombin
time, and platelets. They concluded that
normothermic systemic perfusion did not
influence the clinical course or the extent
of inflammatory and hemostatic activa-
tion in patients undergoing primary iso-
lated coronary artery bypass. The mark-
ers were determined before surgical
inetervention; 21, 48, and 72 hours thereaf-
ter; and at hospital discharge.
We2 previously investigated platelet ac-
tivation and aggregation up to 24 hours
after operation by examining the serial
changes of platelet count and small particle
formation in patients undergoing coronary
artery bypass with normothermic cardio-
pulmonary bypass (CPB). Platelet counts
decreased during CPB, and 24 hours after
CPB they had increased to approximately
half the pre-CPB levels. Small particle for-
mation was the main type of platelet aggre-
gation observed before surgery. Medium
particle formation was also recognized, but
no patient had large particle formation. Af-
ter systemic heparinization, small and me-
dium particle formation occurred. One
hour after the initiation of CPB, only small
particles were seen; 2 hours after the end of
CPB, no small particles were observed.
Small particle formation was the main
platelet aggregation type observed 24 hours
after CPB.
We3 also evaluated cytokine production
and levels of thrombomodulin and soluble
endothelium-derived adhesion molecules
in patients undergoing coronary artery by-
pass under normothermic CPB. The study
was scheduled also up to 24 hours after the
operation. IL-6 values were elevated min-
imally after 30 minutes of CPB, and they
showed a surge at the end of CPB or 2
hours after CPB in some patients. Other
patients showed stable levels. The IL-6 val-
ues were reduced after 2 hours, but 24
hours after CPB they were still higher than
the initial levels. There was a huge differ-
ence in IL-6 changes among patients. A
surge of IL-8 occurred 2 hours after CPB,
and the values returned to the initial levels
24 hours after CPB. Thrombomodulin lev-
els were reduced 30 minutes after the ini-
tiation of CPB; however, they began to
recover during CPB. The levels returned to
the initial levels 2 hours after CPB and
exceeded them 24 hours after CPB. Levels
of soluble endothelium-derived adhesion
molecules were reduced after 30 minutes of
CPB; they returned to the initial levels 2
hours after CPB and exceeded them 24
hours after CPB.
Our studies may endorse the conclu-
sions of Gaudino and associates. CPB for
less than 3 hours does not influence clinical
outcomes, and in vitro studies, such as
platelet function and cytokine production,
did not differ under normothermic and
moderate hypothermic conditions.
Yoshio Misawa, MD
Katsuo Fuse, MD
Division of Cardiovascular Surgery
Jichi Medical School
3311-1 Yakushiji, Minami-kawachi
Tochigi, 329-0498, Japan
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Reply to the Editor:
In contrast to the studies quoted by Misawa
and Fuse, our investigation was aimed at
comparing the effect of normothermic ver-
sus hypothermic cardiopulmonary bypass
(CPB) on postoperative hemostasis and in-
flammatory activation. For this purpose,
patients were randomly assigned to one of
the two CPB temperatures (37°C vs 28°C),
and several inflammatory and coagulative
markers were evaluated at different time
intervals in the postoperative period. We
found no difference between the two
groups and concluded that, at least for our
CPB times, CPB temperature has no effect
on postoperative hemostasis and inflamma-
tory activation.
However, we congratulate Misawa and
Fuse for their interesting studies on the
effects of normothermic CPB on platelet
function and cytokine production and we
applaud their efforts to clarify the systemic
effects of normothermia.
Mario Gaudino, MD
Gianfederico Possati, MD
Department of Cardiac Surgery
Catholic University
Rome, Italy
doi:10.1067/mtc.2003.267
An economic evaluation of lung
transplantation
To the Editor:
In the March 2002 issue of this Journal,
Anyanwu and associates1 reported a prospec-
tive multicenter study about cost-effective-
ness and cost-utility for the different types of
lung transplantation. Although the study is an
important addition to the existing literature,
the method by which survival gain was cal-
culated and the impact on their sensitivity
analyses should be discussed further.
First, in the presented study Anyanwu and
associates1 calculated survival for the first 4
years from actual data and from years 4 to 15
by using a parametric Weibull model, in ac-
cordance with a previous analysis by our
group.2 At 15 years, the survival curve after
transplantation was cut off despite a survival
of at least 25%, depending on the type of
transplantation. Survival on the waiting list
declined to 0% after 11 years. For a valid
comparison of costs and effects of both con-
ditions from a lifetime perspective, a survival
curve after transplantation should be con-
structed with further extrapolation until a sur-
vival of 0%.3,4 Therefore the survival after
lung transplantation in the presented study
was underestimated, because prolonged sur-
vival beyond 15 years was neglected. A
rough calculation indicates that extrapolation
to 0% survival would amount to an estimated
additional survival gain after transplantation
of 2 years. This is why, in contrast to others,5
Anyanwu and colleagues1 did not find sur-
vival as a principal determinant of cost-effec-
tiveness in their sensitivity analyses.
Second, the survival curve for the wait-
ing list, to which the survival after lung
transplantation was compared, was not
constructed in accordance with previously
reported methods.3,4 In previous studies the
transplantation date was chosen as the
starting point for this comparison, because
it would be unrealistic to assume that dif-
ferences in survival occur before transplan-
tation. For the situation on the waiting list,
no real transplantation date exists, and a
fictitious transplantation moment should be
created (Figure 1). This moment should be
based on the average stay of patients on the
waiting list before transplantation (about
12 months in the study by Anyanwu and
associates1). However, day 0 was used as
the starting point for the waiting list. Ap-
plied to our own data, these two methods
result in a difference in the cumulative
number of life years on the waiting list of
0.5 years (17%).
Obviously, changing the method for the
calculation of survival gain will also influ-
ence the number of quality-adjusted life years
gained. It is possible that this would affect the
results of the sensitivity analyses with respect
Figure 1. Actual waiting list survival, fictitious waiting list survival, and survival after
lung transplantation (LTx) in Groningen lung transplant program, 1990 through 1995.
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